3 Firms Steer Menarini's Stemline Deal Worth Up To $677M
Italian pharmaceutical company Menarini said Monday it plans to acquire Stemline, the New York-based maker of a cancer drug, in a deal worth up to $677 million steered by Fried Frank,...To view the full article, register now.
Already a subscriber? Click here to view full article